# Multiomics in silico analysis identifies TM4SF4 as a cell surface target in hepatocellular carcinoma

**Authors:** Kah Keng Wong, Suzina Sheikh Ab. Hamid, Mahmood S Choudhery, Mahmood S Choudhery, Mahmood S Choudhery

PMC · DOI: 10.1371/journal.pone.0307048 · 2025-02-25

## TL;DR

This study identifies TM4SF4 as a potential cell surface target for treating hepatocellular carcinoma with reduced toxicity to normal tissues.

## Contribution

TM4SF4 is proposed as a novel cell surface target for HCC immunotherapy with favorable expression profiles and oncogenic associations.

## Key findings

- TM4SF4 showed significantly higher expression in HCC compared to seven other common HCC targets.
- TM4SF4 is absent in immune cells and expressed in hepatocyte regions inaccessible to immune cells.
- TM4SF4 expression correlates with mitochondrial and oxidative phosphorylation pathways in HCC cells.

## Abstract

The clinical application of cellular immunotherapy in hepatocellular carcinoma (HCC) is impeded by the lack of a cell surface target frequently expressed in HCC cells and with minimal presence in normal tissues to reduce on-target, off-tumor toxicity. To address this, an in silico multomics analysis was conducted to identify an optimal therapeutic target in HCC. A longlist of genes (n = 12,948) expressed in HCCs according to The Human Protein Atlas database were examined. Eight genes were shortlisted to identify one with the highest expression in HCCs, without being shed into circulation, and with restrictive expression profile in other normal human tissues. A total of eight genes were shortlisted and subsequently ranked according to the combination of their transcript and protein expression levels in HCC cases (n = 791) derived from four independent datasets. TM4SF4 was the top-ranked target with the highest expression in HCCs. TM4SF4 showed more favorable expression profile with significantly lower expression in normal human tissues but more highly expressed in HCC compared with seven other common HCC therapeutic targets. Furthermore, scRNA-seq and immunohistochemistry datasets showed that TM4SF4 was absent in immune cell populations but highly expressed in the bile duct canaliculi of hepatocytes, regions inaccessible to immune cells. In scRNA-seq dataset of HCCs, TM4SF4 expression was positively associated with mitochondrial components and oxidative phosphorylation Gene Ontologies in HCC cells (n = 15,787 cells), suggesting its potential roles in mitochondrial-mediated oncogenic effects in HCC. Taken together, TM4SF4 is proposed as a promising cell surface target in HCC due to its high expression in HCC cells with restricted expression profile in non-cancerous tissues, and association with HCC oncogenic pathways.

## Linked entities

- **Genes:** TM4SF4 (transmembrane 4 L six family member 4) [NCBI Gene 7104]
- **Diseases:** hepatocellular carcinoma (MONDO:0007256), HCC (MONDO:0007256)

## Full-text entities

- **Genes:** TM4SF4 (transmembrane 4 L six family member 4) [NCBI Gene 7104] {aka ILTMP, il-TMP}
- **Diseases:** tumor (MESH:D009369), HCC (MESH:D006528), toxicity (MESH:D064420)
- **Species:** Homo sapiens (human, species) [taxon 9606]

## Figures

19 figures with captions in the complete paper: https://tomesphere.com/paper/PMC11856526/full.md

---
Source: https://tomesphere.com/paper/PMC11856526